Clover Health Investments (NASDAQ:CLOV) Trading Down 4.5% - Here's What Happened

Clover Health Investments, Corp. (NASDAQ:CLOV - Get Free Report) dropped 4.5% during trading on Wednesday . The stock traded as low as $4.43 and last traded at $4.39. Approximately 1,149,289 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 6,965,554 shares. The stock had previously closed at $4.59.

Wall Street Analysts Forecast Growth

CLOV has been the subject of several recent analyst reports. Craig Hallum assumed coverage on shares of Clover Health Investments in a report on Tuesday, December 17th. They issued a "buy" rating and a $6.00 price target for the company. UBS Group assumed coverage on shares of Clover Health Investments in a research note on Monday, October 7th. They set a "neutral" rating and a $4.00 target price on the stock.

Clover Health Investments Stock Performance

The firm's 50 day simple moving average is $3.54 and its 200-day simple moving average is $3.18. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -22.08 and a beta of 1.95.

Clover Health Investments (NASDAQ:CLOV - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.01. The firm had revenue of $330.99 million for the quarter, compared to analysts' expectations of $347.60 million. Clover Health Investments had a negative net margin of 5.92% and a negative return on equity of 25.46%. During the same quarter in the previous year, the company posted ($0.09) EPS. As a group, sell-side analysts expect that Clover Health Investments, Corp. will post -0.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CLOV. Geode Capital Management LLC raised its position in shares of Clover Health Investments by 21.9% during the 3rd quarter. Geode Capital Management LLC now owns 4,828,701 shares of the company's stock worth $13,622,000 after acquiring an additional 868,501 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Clover Health Investments by 5.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,000,505 shares of the company's stock valued at $8,461,000 after purchasing an additional 150,550 shares during the last quarter. State Street Corp grew its stake in Clover Health Investments by 65.0% during the 3rd quarter. State Street Corp now owns 2,189,380 shares of the company's stock worth $6,174,000 after buying an additional 862,621 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Clover Health Investments by 75.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,128,171 shares of the company's stock worth $3,181,000 after buying an additional 485,987 shares during the period. Finally, AQR Capital Management LLC increased its position in Clover Health Investments by 4.6% during the second quarter. AQR Capital Management LLC now owns 729,706 shares of the company's stock worth $898,000 after buying an additional 32,288 shares during the period. Hedge funds and other institutional investors own 19.77% of the company's stock.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.